{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:04:57Z","timestamp":1784034297694,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"National Science and Technology Major Project of China for Significant New Drugs Creation","award":["2019ZX09302053"],"award-info":[{"award-number":["2019ZX09302053"]}]},{"name":"National Science and Technology Major Project of China for Significant New Drugs Creation","award":["2020ZX09101027"],"award-info":[{"award-number":["2020ZX09101027"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s40121-023-00872-4","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T04:02:13Z","timestamp":1697688133000},"page":"2595-2609","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Alfosbuvir plus Daclatasvir for Treatment of Chronic Hepatitis C Virus Infection in China"],"prefix":"10.1007","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct04070235","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Rui","family":"Hua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuexin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxin","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueji","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiefei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujuan","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfang","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuebing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingren","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqi","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojiong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongning","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hainv","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youwen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongliang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongliang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghua","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinsheng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqi","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"issue":"suppl 2","key":"872_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1478-3231.2011.02540.x","volume":"31","author":"W Sievert","year":"2011","unstructured":"Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, et al. A systematic review of hepatitis C virus epidemiology in Asia Australia and Egypt. Liver Int. 2011;31(suppl 2):61\u201380.","journal-title":"Liver Int"},{"issue":"1","key":"872_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12985-017-0710-z","volume":"14","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Chen LM, He M. Hepatitis C Virus in mainland China with an emphasis on genotype and subtype distribution. Virol J. 2017;14(1):41.","journal-title":"Virol J"},{"key":"872_CR3","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.ijid.2022.06.017","volume":"122","author":"TT Yue","year":"2022","unstructured":"Yue TT, Zhang QQ, Cai T, Xu M, Zhu HZ, Pourkarim MR, et al. Trends in the disease burden of HBV and HCV infection in China from 1990\u20132019. Int J Infect Dis. 2022;122:476\u201385.","journal-title":"Int J Infect Dis"},{"issue":"6","key":"872_CR4","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1111\/jgh.14102","volume":"33","author":"L Wei","year":"2018","unstructured":"Wei L, Xie Q, Hou JL, Jia JD, Li W, Xu M, et al. Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: results from a phase 3b study in China. J Gastroenterol Hepatol. 2018;33(6):1168\u201376.","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"872_CR5","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s12072-018-9856-z","volume":"12","author":"L Wei","year":"2018","unstructured":"Wei L, Xie Q, Hou JL, Tang H, Ning Q, Cheng J, et al. Ledipasvir\/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study. Hepatol Int. 2018;12(2):126\u201332.","journal-title":"Hepatol Int"},{"issue":"5","key":"872_CR6","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/hep4.1049","volume":"1","author":"N Reau","year":"2017","unstructured":"Reau N, Vekeman F, Wu E, Bao YJ, Gonzalez YS. Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy. Hepatol Commun. 2017;1(5):439\u201352.","journal-title":"Hepatol Commun"},{"issue":"6","key":"872_CR7","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/jvh.13650","volume":"29","author":"R Hua","year":"2022","unstructured":"Hua R, Kong F, Wen XF, Xiong QF, Chen JY, Meng CX, et al. Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection: an open-label, phase 2 study. J Viral Hepat. 2022;29(6):455\u201364.","journal-title":"J Viral Hepat"},{"key":"872_CR8","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1021\/jm500335h","volume":"57","author":"M Belema","year":"2014","unstructured":"Belema M, Meanwell NA. Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect. J Med Chem. 2014;57:5057\u201371.","journal-title":"J Med Chem"},{"issue":"8","key":"872_CR9","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1056\/NEJMoa1503153","volume":"373","author":"DL Wyles","year":"2015","unstructured":"Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373(8):714\u201325.","journal-title":"N Engl J Med"},{"key":"872_CR10","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69:461\u2013511.","journal-title":"J Hepatol"},{"issue":"11","key":"872_CR11","volume":"6","author":"Y Chen","year":"2017","unstructured":"Chen Y, Yu CS, Yin XR, Guo XL, Wu SW, Hou JL. Hepatitis C virus genotypes and subtypes circulating in Mainland China. Emerg Microbes Infect. 2017;6(11): e95.","journal-title":"Emerg Microbes Infect"},{"issue":"7","key":"872_CR12","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/jmv.25454","volume":"91","author":"R Huang","year":"2019","unstructured":"Huang R, Rao HY, Xie Q, Gao ZL, Li W, Jiang DY, et al. Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infection. J Med Virol. 2019;91(7):1313\u20138.","journal-title":"J Med Virol"},{"issue":"3","key":"872_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/CM9.0000000000000629","volume":"133","author":"N Wu","year":"2020","unstructured":"Wu N, Rao HY, Yang WB, Gao ZL, Yang RF, Fei R, et al. Impact of hepatitis C virus genotype 3 on liver disease progression in a Chinese national cohort. Chin Med J (Engl). 2020;133(3):253\u201361.","journal-title":"Chin Med J (Engl)"},{"issue":"27","key":"872_CR14","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"373","author":"JJ Feld","year":"2015","unstructured":"Feld JJ, Jacobson IM, H\u00e9zode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599\u2013607.","journal-title":"N Engl J Med"},{"issue":"11","key":"872_CR15","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1111\/liv.14633","volume":"40","author":"Y Gao","year":"2020","unstructured":"Gao Y, Kong F, Li G, Li C, Zheng S, Lin J, et al. Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: a single-arm, open-label, phase 3 trial. Liver Int. 2020;40(11):2685\u201393.","journal-title":"Liver Int"},{"issue":"20","key":"872_CR16","first-page":"30086","volume":"S2468\u20131253","author":"L Wei","year":"2020","unstructured":"Wei L, Wang G, Alami N, et al. Glecaprevir\u2013pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies\u2014 a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2). Lancet Gastroenterol Hepatol. 2020;S2468\u20131253(20):30086\u20138.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"872_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S2468-1253(18)30343-1","volume":"4","author":"L Wei","year":"2019","unstructured":"Wei L, Lim S, Xie Q, et al. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. Lancet Gastroenterol Hepatol. 2019;4:127\u201334.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"872_CR18","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/jgh.12398","volume":"29","author":"H Rao","year":"2014","unstructured":"Rao H, Wei L, Lopez-Talavera J, et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2014;29:545\u201353.","journal-title":"J Gastroenterol Hepatol"},{"key":"872_CR19","doi-asserted-by":"crossref","unstructured":"Gao Y, Niu J, Kong F, et al. Pan-genotypic regimen of coblopasvir plus sofosbuvir for treatment of chronic hepatitis C in China: a single-arm, open-label, phase 3 trial. AASLD 2019.","DOI":"10.1111\/liv.14633"},{"issue":"13","key":"872_CR20","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.3748\/wjg.v23.i13.2355","volume":"23","author":"D Endo","year":"2017","unstructured":"Endo D, Satoh K, Shimada N, Hokari A, Aizawa Y. Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C genotype 1b. World J Gastroenterol. 2017;23(13):2355\u201364.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"872_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s12664-019-00935-w","volume":"38","author":"A Jain","year":"2019","unstructured":"Jain A, Kalra BS, Srivastava S, Chawla S. Effect of sofosbuvir and daclatasvir on lipid profile, glycemic control and quality of life index in chronic hepatitis C, genotype 3 patients. Indian J Gastroenterol. 2019;38(1):39\u201343.","journal-title":"Indian J Gastroenterol"},{"issue":"9","key":"872_CR22","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.3390\/jcm9092702","volume":"9","author":"C Graf","year":"2020","unstructured":"Graf C, Welzel T, Bogdanou D, Vermehren J, Beckel A, Bojunga J, et al. Hepatitis C clearance by direct-acting antivirals impacts glucose and lipid homeostasis. J Clin Med. 2020;9(9):2702.","journal-title":"J Clin Med"},{"issue":"3","key":"872_CR23","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3390\/cells8030252","volume":"8","author":"MA Doyle","year":"2019","unstructured":"Doyle MA, Galanakis C, Mulvihill E, Crawley A, Cooper CL. Hepatitis C direct acting antivirals and ribavirin modify lipid but not glucose parameters. Cells. 2019;8(3):252.","journal-title":"Cells"},{"issue":"3","key":"872_CR24","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/hep.27581","volume":"61","author":"M Romero-G\u00f3mez","year":"2015","unstructured":"Romero-G\u00f3mez M, Rojas \u00c1. Sofosbuvir modulates the intimate relationship between hepatitis C virus and lipids. Hepatology. 2015;61(3):744\u20137.","journal-title":"Hepatology"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-023-00872-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-023-00872-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-023-00872-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T16:17:09Z","timestamp":1700065029000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-023-00872-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["872"],"URL":"https:\/\/doi.org\/10.1007\/s40121-023-00872-4","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,19]]},"assertion":[{"value":"17 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Xiaomeng Zhang, Jie Min, and Xinsheng Shi are employees of Nanjing Sanhome Pharmaceutical Co., Ltd. The other authors have no conflict of interest to declare. Rui Hua, Fei Kong, Guangming Li, Xiaofeng Wen, Yuexin Zhang, Xingxiang Yang, Chenxin Meng, Wen Xie, Yongfang Jiang, Xiaozhong Wang, Xueji Han, Yan Huang, Qing Mao, Jiefei Wang, Yujuan Guan, Jiayu Chen, Yingjie Ma, Qingfang Xion, Hong Ma, Xuebing Yan, Huiying Rao, Yingren Zhao, Tong Sun, Liying Zhu, Xiaorong Mao, Jianqi Lian, Guojiong Deng, Yongning Xin, Yifei Wang, Yinong Ye, Bin Xu, Hainv Gao, Youwen Tan, Dongliang Li, Dongliang Yang, Minghua Su, Junqi Niu, and Lai Wei have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was carried out by 35 centers, including the First Hospital of Jilin University. Relevant clinical trial protocols, informed consent, case report forms, and researcher manuals were reviewed by the Ethics Committee of the First Hospital of Jilin University for the first time on 26 December 2018, and the opinion was \u201cagree\u201d with ethics approval no. 18Y248-001.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Written informed consent was obtained from all patients prior to enrollment and initiation of any study procedures. The study was approved by an independent ethics committee at each participating site, and we obtained ethics committee approval from all 35 research centers prior to the study commencing. It is carried out in accordance with the principles of the Declaration of Helsinki, China\u2019s legal and regulatory requirements, and good clinical practice. The trial was conducted in mainland China, and no IRB approval was sought.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}